Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy

Christoforidou, Artemis; Goudakos, John; Bobos, Mattheos; Lefkaditis, Efthimios; Vital, Victor; Markou, Konstantinos

doi:10.1016/j.amjoto.2012.12.016

Cited by 22 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same is true for induced sarcoidosis, which may be limited to 1 organ [4, 7, 8, 9, 10, 11]. For example, it has been reported to present very atypically and involve just the hypopharynx [13]. …”

Section: Discussionmentioning

confidence: 99%

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Moisseiev

Shulman

2014

Case Rep Ophthalmol

View full text Add to dashboard Cite

We report the case of a 64-year-old woman with rheumatoid arthritis and bilateral visual deterioration. The patient had been treated with certolizumab, a new tumor necrosis factor alpha (TNFα) antagonist, and her findings were consistent with bilateral uveitis, suggestive of sarcoidosis. Here, we review the literature on TNFα antagonist-induced sarcoidosis and report the first case of uveitis induced by certolizumab. Awareness of the possibility of this unique complication is important for both rheumatologists and ophthalmologists who treat patients with this new agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Moisseiev

Shulman

2014

Case Rep Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Those observations led them to raise the possibility that the -857 genotype of the TNFa promoter may affect its expression at the protein level in the absence of other confounding factors, such as the possible effect of AS on TNFa level, and they also concluded that the impact of -857T allele on TNFa expression does exist (21). Tong et al reported that -857C allele showed better responsiveness than -857T allele to the TNF inhibitors and the -857C/C genotype is predictor of good response in spondyloarthritis, inflammatory bowel disease and ankylosing spondylitis patients (23,24). Vasilopoulos et al (25) also reported that carriage of -857C allele was associated with positive response to pharmacotherapy in patients treated with etanercept which is one of the TNF inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…Tong et al reported that ‐857C allele showed better responsiveness than ‐857T allele to the TNF inhibitors and the ‐857C/C genotype is predictor of good response in spondyloarthritis, inflammatory bowel disease and ankylosing spondylitis patients . Vasilopoulos et al also reported that carriage of ‐857C allele was associated with positive response to pharmacotherapy in patients treated with etanercept which is one of the TNF inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Effects of tumor necrosis factor α‐857C/T polymorphism on the expression of tumor necrosis factor α

Kimura

Takayanagi

Yokoyama

et al. 2016

APMIS

View full text Add to dashboard Cite

It was reported that homozygosity for a lymphotoxin α (LTA) 1-1-1-1 haplotype (LTA NcoI-TNFc-aa13L-aa26) may identify subgroups with a poor response to infliximab in Crohn's disease patients. Previously, we found a genetic polymorphism that linked with the LTA 1-1-1-1 haplotype and noted that it was a tumor necrosis factor (TNF) α-857 T allele. To investigate the effects of the -857C/T (rs1799724) polymorphism on the expression of TNFα, we compared levels of transcriptional activity of the gene, mRNA, and protein of the TNFα. The change in transcriptional activity of the -857T allele was higher than that of the -857C allele. Furthermore, the accumulated transcriptional activity of the -857T allele was 1.3-fold higher than that of the -857C allele up to 48 h. The levels of mRNA and protein of the TNFα after stimulation were also shown to be significantly higher in -857C/T as compared to the -857C/C genotype. Our results suggested that TNFα promoter -857T is higher than -857C in the levels of transcriptional activity of the gene, mRNA, and protein of the TNFα. The differences in therapeutic effect of TNF inhibitors among individuals can be explained in part by the induction ability of TNFα via the -857C/T polymorphism.

show abstract

“…While there have been multiple studies outlining the positive effects of the therapy, a recent study outlines a potential complication. A patient treated with adalimumab for psoriatic arthritis went on to develop sarcoidosis of the hypopharynx [32]. This has been the first reported case of sarcoidosis of the hypopharynx, and demonstrated a complex clinical scenario in that discontinuation of the drug resulted in resolution of the sarcoidosis.…”

Section: Treatmentmentioning

confidence: 97%

“…This has been the first reported case of sarcoidosis of the hypopharynx, and demonstrated a complex clinical scenario in that discontinuation of the drug resulted in resolution of the sarcoidosis. This is an unforeseen complication of TNF-a therapy resulting in an extremely rare manifestation of sarcoidosis [32].…”

Section: Treatmentmentioning

confidence: 99%

Sarcoidosis of the Head and Neck

Badhey

Kadakia

Carrau

et al. 2014

Head and Neck Pathol

View full text Add to dashboard Cite

Sarcoidosis is a complex disorder that often times involves the head and neck. Despite the presence of strong clinical evidence, tissue diagnosis and imaging is needed for confirmation of the disease. Although typically managed medically, when found in the sinonasal tract or intracranially, it may necessitate the intervention of a rhinologist-skull base surgeon. This article seeks to provide a comprehensive review of head and neck sarcoidosis, as this fascinating disorder often poses a diagnostic and therapeutic challenge. A brief discussion of surgical treatment for pituitary lesions is also provided. Articles from 1997 to 2013 were selected and reviewed by three researchers utilizing the most recent literature regarding sarcoidosis in the head and neck. PubMed searches were conducted using search terms such as "sarcoidosis", "neurosarcoid", and "extra-pulmonary sarcoid", among many others. A large collection of articles was generated and reviewed by the team of authors, and appropriate information was extracted to compose a thorough and expansive review of the subject. 10-15 % of patients with sarcoidosis have head and neck manifestations. Sinonasal and pituitary sarcoidosis presents a diagnostic challenge owing to its non-specific symptoms. Although systemic steroid therapy is often the first time treatment, endoscopic surgery is commonly used to treat advanced pituitary sarcoidosis refractory to medical management. As tissue diagnosis and imaging is key, a multi-disciplinary team approach is advantageous. Our study collates the available literature on head and neck sarcoidosis to provide a comprehensive review of the subject. This provides helpful information to guide all practitioners involved in the care of these challenging patients, namely pathologists, radiologists, otolaryngologists, and skull base surgeons, in the workup and management of head and neck sarcoidosis.

show abstract

Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy

Cited by 22 publications

References 13 publications

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Certolizumab-Induced Uveitis: A Case Report and Review of the Literature

Effects of tumor necrosis factor α‐857C/T polymorphism on the expression of tumor necrosis factor α

Sarcoidosis of the Head and Neck

Contact Info

Product

Resources

About